Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis-Reference-Cited by-同舟云学术

Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis

Published:2021-03-26 Issue:5 Volume:21 Page:535-543
ISSN:1175-3277
Container-title:American Journal of Cardiovascular Drugs
language:en
Short-container-title:Am J Cardiovasc Drugs

Author:

Vong Camille,Boucher Martin,Riley Steve,Harnisch Lutz O.^ORCID

Funder

Pfizer

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40256-021-00464-y.pdf

Reference25 articles.

1. Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10:1086–97.

2. Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23:S107–12.

3. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126:1286–300.

4. Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation. 2016;133:282–90.

5. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:2872–91.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review;Journal of Comparative Effectiveness Research;2024-07

2. Atrial Fibrillation as a Prognostic Factor for All-Cause Mortality in Patients With Transthyretin Amyloid Cardiomyopathy;JACC: CardioOncology;2024-04

3. Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis;eClinicalMedicine;2023-09

4. Sex differences in transthyretin cardiac amyloidosis;Heart Failure Reviews;2023-08-11

5. Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy;International Journal of Molecular Sciences;2022-12-18